Oncology Venture gets option to in-license European rights to IXEMPRA
Category: #headlines  By Nikita Chaurasia  Date: 2019-04-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Milacron partnership agreement with iMPLUX to revolutionize molding
Milacron partnership agreement with iMPLUX to revolutionize molding
By Nikita Chaurasia

Milacron Holdings Corp., a technology company known for its services to the plastics processing industry recently announced the signing of a proprietary partnership with iMFLUX, a wholly owned subsidiary of Proctor & Gamble. The distribution agre...

Percona unveils optimized version of database monitoring platform PMM2
Percona unveils optimized version of database monitoring platform PMM2
By Nikita Chaurasia

Percona, a leading provider of open source database software and services based in America, has recently unveiled Percona Monitoring and Management 2 (PMM2), an upgraded version of its award-winning database management platform at the 2019 Percona Li...

Tastewise raises $5 million in a funding round led by PeakBridge
Tastewise raises $5 million in a funding round led by PeakBridge
By Nikita Chaurasia

Tastewise to develop its food intelligence platform with the new funding. An intelligence startup Tastewise, that offers data, analytics and insights platform for food brands and restaurants, recently announced that it has collected USD $5 million i...